However, few trials have specifically assessed the efficacy of drugs targeting the IL-6 pathway in the acute setting of cardiovascular disease, providing early signals supporting its feasibility, thus offering a rationale for further investigation in CS. Here, IL6 is linked to cardiovascular disorder.